From Wikipedia, the free encyclopedia
Monoclonal antibody
Boserolimab (MK-5890) is a
monoclonal antibody in development for
lung cancer. It is developed by
Merck.
[1]
[2]
[3]
References
-
^ Peled, N.; Rodriguez-Abreu, D.; Bordoni, R.; Ellis, P.M.; Hochmair, M.; Müller, V.; Levchenko, E.; Zhou, H.; Zhao, B.; Lara-Guerra, H.; Ahn, M-J. (December 2021).
"114TiP KEYNOTE-B99: Phase II study of pembrolizumab plus investigational agents combined with chemotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC)". Annals of Oncology. 32: S1425.
doi:
10.1016/j.annonc.2021.10.132.
-
^ Guelen, Lars; Fischmann, Thierry O; Wong, Jerelyn; Mauze, Smita; Guadagnoli, Marco; Bąbała, Nikolina; Wagenaars, Jozef; Juan, Veronica; Rosen, David; Prosise, Winnie; Habraken, Maurice; Lodewijks, Imke; Gu, Danling; Stammen-Vogelzangs, Judith; Yu, Ying; Baker, Jeanne; Lutje Hulsik, David; Driessen-Engels, Lilian; Malashock, Dan; Kreijtz, Joost; Bertens, Astrid; de Vries, Evert; Bovens, Astrid; Bramer, Arne; Zhang, Yiwei; Wnek, Richard; Troth, Sean; Chartash, Elliot; Dobrenkov, Konstantin; Sadekova, Svetlana; van Elsas, Andrea; Cheung, Jason K; Fayadat-Dilman, Laurence; Borst, Jannie; Beebe, Amy M; Van Eenennaam, Hans (13 September 2022).
"Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy". Journal for Immunotherapy of Cancer. 10 (9): e005049.
doi:
10.1136/jitc-2022-005049.
ISSN
2051-1426.
PMC
9472132.
PMID
36100308.
-
^ Wickramarachchi, Dilki; Wagner, Julianne; Woo, Thomas; Ferrari, Federico; Steinmetz, Thomas; Helmy, Roy; Xu, Weifeng (25 January 2023). "A Novel Neutralization Antibody Assay Method to Overcome Drug Interference with Better Compatibility with Acid-Sensitive Neutralizing Antibodies". The AAPS Journal. 25 (1): 18.
doi:
10.1208/s12248-023-00783-9.
PMID
36697923.
S2CID
256267804.